非布司他治什么？

Also known as Febuxostat, it was developed in Japan in 2004, approved for marketing by European EMEA in 2008, approved for marketing by the US FDA in 2009, and approved for marketing by the China State Food and Drug Administration in 2013. So, what does Febuxostat treat?

Indications of Febuxostat: Mainly used to treat gout, gouty arthritis, gout in the elderly, hyperuricemia, pseudogouty arthritis, tophi, hereditary hyperuricemia. The main ingredient of Febuxostat tablets is Febuxostat.

Febuxostat is a xanthine oxidase (XO) inhibitor that reduces serum uric acid concentration by inhibiting uric acid synthesis. However, febuxostat is not recommended for the treatment of asymptomatic hyperuricemia.

In addition, there are many symptoms of gout, the most important of which is the disorder of the body's metabolic function, which reduces the excretion of uric acid in the body and increases the uric acid value in the body, thereby causing gout. Increased uric acid is the basis and most direct risk factor for the occurrence of gout. Febuxostat can inhibit the synthesis of uric acid, thereby reducing the concentration of serum uric acid, and plays a role in the treatment of gout.

In addition, patients should also pay attention to the following when using febuxostat:

On April 1, 2016, Health Canada released information stating that after discovering some suspected cases of heart failure related to the use of febuxostat, Health Canada conducted a safety review and required the manufacturer of febuxostat to include a statement in its prescribing information regarding the possible increased risk of heart failure in patients with existing cardiovascular disease risk factors.

On November 15, 2017, the U.S. Food and Drug Administration (FDA) issued a safety warning announcement stating that preliminary results from a safety clinical trial showed that the anti-gout drug febuxostat may increase the risk of heart-related death compared with allopurinol.

Heart poisoning issues require special attention! The drug package inserts already contain a warning and precaution about cardiovascular events, including heart attack, stroke, and heart-related death.